Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes.
sex differences, genomic data, splicing machinery mutations
somatic mutations
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
01
09
2022
revised:
28
12
2022
accepted:
11
01
2023
pmc-release:
01
05
2024
medline:
21
4
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Introduction/Background The impact of biological sex on the clinical phenotype, genotype, and outcomes among patients with MDS is not well characterized. Materials and Methods We retrospectively reviewed the clinical and genomic data from male and female patients included in our institutional MDS database at Moffitt Cancer Center. Results Among 4580 patients with MDS, 2922 (66%) were men and 1658 (34%) were women. Women were younger (mean age 66.5 vs. 69 years for men, P < .001) at diagnosis. There were more Hispanic/black women than men (9% vs. 5%, P =<.001). Women had lower hemoglobin and higher platelet counts than men. More women had del 5q/monosomy 5 abnormalities compared to men (P =<.001). Therapy related MDS were more common in women than men (25% vs.17%, P=<.001). On assessment of molecular profile, SRSF2, U2AF1, ASXL1, and RUNX1 mutations were more frequent in men. The median overall survival (mOS) was 37.5 months (mo) for females compared to 35 monthsfor males, (P = .002). The mOS was significantly prolonged for women in lower-risk MDS, but not in higher-risk MDS. Women were more likely to respond to immunosuppression with ATG/CSA than men (38% vs. 19%, P= 0.04).Conclusion Ongoing research is needed for understanding the impact of sex on phenotype, genotype, and outcomes in patients diagnosed with MDS.
Identifiants
pubmed: 36813626
pii: S2152-2650(23)00020-4
doi: 10.1016/j.clml.2023.01.007
pmc: PMC10121764
mid: NIHMS1865955
pii:
doi:
Substances chimiques
Splicing Factor U2AF
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
355-359Subventions
Organisme : NINR NIH HHS
ID : K23 NR018488
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Références
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807519
Lancet Haematol. 2023 Feb;10(2):e117-e128
pubmed: 36436542
Br J Haematol. 2021 Jun;193(6):1142-1150
pubmed: 34028801
Nature. 1974 Oct 4;251(5474):437-8
pubmed: 4421285
Adv Exp Med Biol. 2021;1304:227-258
pubmed: 34019273
Leukemia. 2015 Jul;29(7):1502-13
pubmed: 25721895
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
Haematologica. 2017 Jan;102(1):85-93
pubmed: 27540137
J Cancer. 2019 Jan 30;10(5):1325-1332
pubmed: 30854142
Blood. 2006 Jul 15;108(2):419-25
pubmed: 16609072
Int J Hematol. 2012 Oct;96(4):438-42
pubmed: 23054646
Leuk Lymphoma. 2017 Jun;58(6):1325-1331
pubmed: 27774847
Expert Rev Cardiovasc Ther. 2012 Nov;10(11):1401-11
pubmed: 23244361
Biomol Ther (Seoul). 2018 Jul 1;26(4):335-342
pubmed: 29949843
Haematologica. 2014 Jun;99(6):1088-94
pubmed: 24658818
Nat Rev Cancer. 2004 Aug;4(8):617-29
pubmed: 15286741
Blood Adv. 2020 Jun 23;4(12):2567-2576
pubmed: 32542392
Leukemia. 2005 Jun;19(6):984-9
pubmed: 15830009
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254